Table 1

Baseline characteristics and demographics of patients

Dulaglutide 1.5 mgDulaglutide 0.75 mgGlargine
VariableN = 273N = 272N = 262
Sex, n (%)
 Men144 (53)136 (50)134 (51)
 Women129 (47)136 (50)128 (49)
Age (years)56 ± 1057 ± 957 ± 9
Race, n (%)
 American Indian or Alaska Native29 (11)31 (11)29 (11)
 Asian48 (18)46 (17)43 (16)
 Black or African American1 (<1)1 (<1)2 (1)
 Multiple2 (1)1 (<1)4 (2)
 White193 (71)193 (71)184 (70)
Ethnicity, n (%)
 Hispanic98 (36)96 (35)97 (37)
 Non-Hispanic175 (64)176 (65)165 (63)
Weight (kg)85 ± 1886 ± 1888 ± 20
BMI (kg/m2)31 ± 532 ± 532 ± 6
Diabetes duration (years)9 ± 69 ± 69 ± 6
HbA1c (%)8.2 ± 1.08.1 ± 1.08.1 ± 1.0
HbA1c (mmol/mol)65.9 ± 11.365.4 ± 10.765.0 ± 10.4
Fasting serum glucose (mg/dL)165 ± 49161 ± 49163 ± 48
Glimepiride dose (mg/day)6.3 ± 1.76.3 ± 1.66.2 ± 1.6
Metformin dose (mg/day)2,379 ± 4802,412 ± 4952,419 ± 475
Prestudy treatment (%)*
 1 OAM16.515.416.2
 2 OAMs67.865.466.4
 >2 OAMs15.819.117.4
  • Data are mean ± SD or n (%) unless otherwise indicated.

  • *At screening.